夺宝岛


您好!欢迎访问夺宝岛官方网站。
服务热线:0571-86130357     | 在线反馈English
夺宝岛 / News Center
夺宝岛BPI-D0316项目II期临床完成受试者入组
日期: 2020-07-29

       7YUE29RI,夺宝岛DISANDAIBIAOPISHENGZHANGYINZISHOUTILAOANSUANJIMEIYIZHIJI(EGFR-TKI)BPI-D0316ZAIEGFRTUBIANJUBUWANQIHUOZHUANYIXINGFEIXIAOXIBAOFEIAIHUANZHEZHONGDEIIQILINCHUANGSHIYANRUZUZUIHOU1LISHOUSHIZHE,ZHENGSHIWANCHENGSHOUSHIZHERUZU。

       BPI-D0316SHIZHENDUIT790MTUBIANDEDISANDAIEGFR-TKI。BIAOPISHENGZHANGYINZISHOUTI(EGFR)SHIFEIXIAOXIBAOFEIAIZHUYAODEZHIAIQUDONGYINZI,EGFR-TKINENGTEYIXINGDIYIZHIEGFRDEHUOXING,CONGERDADAOYIZHIZHONGLIUXIBAODEMUDE。MUQIANZHENDUIEGFRTUBIANFEIXIAOXIBAOFEIAIDEZHILIAO,YIDIYIDAIEGFR-TKIWEIZHU,DANHUANZHEZAIJIESHOUDIYIDAIEGFR-TKIZHILIAOYIDINGSHIJIANHOUWANGWANGHUICHANSHENGNAIYAOTUBIAN,QIZHONGT790MTUBIANZHAN60%YISHANG。YANJIUBIAOMING,ZHENDUIT790MTUBIANDEDISANDAIEGFR-TKINENGGOUXIANZHUGAISHANHUANZHEDESHENGCUNZHILIANG,TIGAOHUANZHEDEZONGSHENGCUNQI。  

BPI-D0316作用机理图

       BPI-D0316ZAIGUONEIIQILINCHUANGSHIYANZHONGBIAOXIANYOUXIU,IIQILINCHUANGSHIYANYOUSHANGHAIJIAOTONGDAXUEFUSHUXIONGKEYIYUANZHONGLIUKEZHURENLUSHUNJIAOSHOUQIANTOU,QUANGUOGONGJI51JIAYANJIUZHONGXINCANJIA。IIQILINCHUANGSHIYANTUIJINQIJIAN,SHIFENGXINGUANFEIYANYIQINGBAOFA,SHOUSHIZHEZHAOMURUZUSHOUDAOHENDAYINGXIANG,YIRUZUDESHOUSHIZHEYEMIANLINDUANYAO、WUFAFANHUIYANJIUZHONGXINJINXINGSUIFANGDAOZHISHUJUQUESHIDENGFENGXIAN。MIANDUIQIANSUOWEIYOUDEJUDATIAOZHAN,夺宝岛XUNSUZUZHIDUOBUMENGOUTONGXIEZUO,DIAOZHENGYOUHUAXIANGMUZIYUAN、JIHUAHECELVE。YIFANGMIANJIZHONGYOUSHIZIYUANJIAKUAIGEYANJIUZHONGXINHUIFURUZU,LINGYIFANGMIANYINDIZHIYIZHIDINGXIANGJIN、DONGTAIDEGENZONG、GUANLICUOSHI。DUIYOUDUANYAOHEWUFAFANHUIFANGSHIFENGXIANDESHOUSHIZHE,XIANGMUZUCHENGYUANKEFUZHONGZHONGKUNNAN,TONGGUOWULIUYOUJISHIYANYONGYAOHEJIUJINYIYUANWANCHENGSUIFANGJIANCHADENGFANGSHI,QUEBAOLESHOUSHIZHEDEYONGYAOHESUIFANG,BAOZHENGLEHUANZHEYONGYAOLIAOXIAOHEANQUANYIJIGUANJIANSHIYANSHUJUDEWANZHENGXING、ZHUNQUEXING。

       DUIYUXIANGMUQIANQITUIJINGUOCHENG,GONGSIGAOJILINCHUANGYANJIUJINGLICHENGHONGKESHUO,ZAISHOUSHIZHEZHAOMUZHONG,GONGSIYIXUEBU、ZHONGLIUSHIYEBU、RENLIZIYUANBU、CAIWUBU、ZHUCESHIWUBUDENGDUOBUMENKEFUZHONGZHONGKUNNANXIETONGZUOZHAN,FENLITUIJINXIANGMUANJIHUADACHENGGUANJIANLICHENGBEI,CHONGFENTIXIANLE夺宝岛JINGCHENGTUANJIE、TONGLIXIEZUO、MUBIAODAOXIANGDEWENHUAYUJINGSHEN,YEZHANGXIANLEDAJIAQUANLITUIJINZHEIYIZHONGDIANGONGGUANXIANGMUDEJUEXINYUXINXIN。

       LINCHUANGGUANLIHEYIXUESHIWUFUZERENJIDONGSHUO,JINGLILEZHONGZHONGJIANNANZUAI,CICIBPI-D0316XIANGMUNENGGOUANZHAOJIHUASHUNLIWANCHENGRUZU,SHIFENBURONGYI,ZHEISHIGONGSISHANGXIATONGLIHEZUOSUOQUDEDECHENGGUO。JIEXIALAI,XIANGMUZUHUIJIXUYIANGYANGDEDOUZHI、JIANDINGDEJUEXIN,BAHAOXIANGMUZHILIANGHESHUJUGUANKA,WEITUIDONGCHANPINJINKUAISHANGSHIDIANDINGJIANSHIDEJICHU。

        公司资深副总裁兼首席医学官毛力教授表示,BPI-D0316项目是夺宝岛构建肿瘤精准医疗生态链的重要举措,有助于加快贝达在肺癌治疗领域的全面覆盖。在项目组的努力和各部门的配合下,II期临床试验达到受试者入组预期节点,克服了各种不可预期的困难,取得了阶段性成果,有望成为夺宝岛近年来继盐酸恩沙替尼、贝伐珠单抗(MIL60)后,第3个申请上市的新药。接下来,希望项目组继续努力,把控细节、把握质量,全力开展好后续工作,争取早日为第一代EGFR-TKI耐药的T790M突变非小细胞肺癌患者提供新的用药选择。
       丁列明博士回顾了BPI-D0316项目从引进到完成入组的历程,“对贝达而言,作为靶向治疗领域的领军企业,BPI-D0316项目是不可或缺的重要一环,凝聚了各部门的心血。”丁博士说,三代EGFR-TKI赛道拥挤,时间紧迫,各部门齐心协力,顶着压力坚决完成任务,非常令人感动。项目的推进也是科学探索的过程,体现着贝达对科研的追求与执着,期待各部门共同做好BPI-D0316项目NDA的相关工作,尽早为肺癌病人带去福音。

公司高管与项目组合影

 

关于夺宝岛:

       夺宝岛GUFENYOUXIANGONGSI(GUPIAODAIMA:)SHIYIJIAYOUHAIGUIGAOCENGCIRENCAITUANDUICHUANGBANDE,YIZIZHUZHISHICHANQUANCHUANGXINYAOWUYANJIUHEKAIFAWEIHEXIN,JIYANFA、SHENGCHAN、YINGXIAOYUYITIDEGUOJIAJIGAOXINJISHUQIYE。ZIZHUYANFALEZHONGGUODIYIGEXIAOFENZIBAXIANGKANGAIYAO——YANSUANAIKETINI(SHANGPINMING:KAIMEINA),BEIYUWEIKANBIMINSHENGLINGYU“LIANGDANYIXING”DEZHONGDATUPO,LIANGHUOZHONGGUOZHUANLIJINJIANG,ZHANHUOWOGUOHUAXUEZHIYAOXINGYEDIYIGEGUOJIAKEJIJINBUYIDENGJIANG。JIEZHI2020NIANDIYIJIDUMO,AIKETINIYIHUIJI25WANMINGWANQIFEIAIHUANZHE,LEIJIXIAOSHOUJIN80YIYUAN。GONGSIJIANLILEWANZHENGDEXINYAOYANFATIXI,ZAIHANGZHOU、BEIJINGFENBIESHEYOUYANFAZHONGXIN,ZAIYANCHUANGXINYAO30YUXIANG,HANGAILEFEIAI、SHENAI、RUXIANAIDENGDUOGEZHONGLIUSHIYINGZHENG。GONGSIYUAmgen、Xcovery、Tyrogenex、Merus、Agenus、TIANGUANGSHI、YIFANGSHENGWUDENGGUONEIWAILINGXIANDEZHIYAOQIYEDACHENGZHANLVEHEZUO,WEICUJINQUANRENLEIDEJIANKANGFUZHIERGONGTONGNULI。


上一条: 恩沙替尼一线数据全球惊艳亮相 全线守护ALK阳性患者
下一条: 喜讯!夺宝岛BPI-17509项目I期临床试验第一例受试者入组

var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?78ebdacae9da971faf025645ab77d367"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })();